RGD (Arg-Gly-Asp) tripeptide is the universal integrin-binding motif present in fibronectin, vitronectin, osteopontin, fibrinogen, and bone sialoprotein. As a research-grade integrin ligand (MW 346 Da; ≥98% purity), RGD is a cornerstone research tool for cell adhesion biology, targeted cancer therapy delivery, integrin pharmacology, 3D tissue engineering scaffold functionalisation, and stem cell microenvironment engineering — with one of the broadest translational research footprints of any synthetic tripeptide. RGD is the core recognition sequence for integrins αvβ3, α5β1, and αIIbβ3. 

Advanced Research Applications:

1. Cell adhesion: Promotes 80-90% cell attachment within 1 hour on RGD-coated surfaces
2. Wound healing: Increases keratinocyte migration rate by 3-fold in scratch assays
3. Tissue engineering: Enhances scaffold bioactivity: 2x cell infiltration vs. control
4. Angiogenesis: Supports endothelial tube formation (HUVEC) at 100 µg/mL
5. Osteogenesis: Upregulates osteocalcin and Runx2 in MSC cultures by 150%
6. Stem Cell Research & Microenvironment Engineering: iPSC and ESC culture as RGD-functionalized PEG hydrogels and VTN-N-mimicking surfaces as xeno-free.
7. Cancer Research — Tumour Targeting, Drug Delivery & Imaging: RGD is the most widely used tumour-targeting motif in translational oncology research, exploiting the selective overexpression of specific integrin subtypes on tumour vasculature and cancer cells vs. quiescent normal tissue:

• Glioblastoma Multiforme (GBM) — Primary Target: αvβ3, αvβ5
• Triple-Negative Breast Cancer (TNBC) — Primary Target: αvβ3, α5β1
• Pancreatic Ductal Adenocarcinoma (PDAC) — Primary Target: αvβ3, αvβ5, α5β1
• Melanoma — Primary Target: αvβ3
• Prostate Cancer — Primary Target: αvβ3
• Ovarian Cancer — Primary Target: αvβ3, αvβ5, α5β1

Key Technical Specifications